Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation

Melanoma Research

Volumn 23, Issue 3, 2013, Pages 221-226

  Veinalde, Ruta ^a   Ozola, Aija ^a   Azarjana, Kristine ^b   Molven, Anders ^d,e   Akslen, Lars A ^d,e   Doniņa, Simona ^c   Proboka, Guna ^c   Čema, Ingrida ^b,c   Baginskis, Ainars ^a   Pjanova, Dace ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

9p21 locus; CDK4; CDKN2A; CDKN2A promoter; deletion analysis; familial melanoma; high risk genes; intronic polymorphisms; multiple ligation dependent probe amplification

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; EXON; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; LATVIA; MALE; MELANOMA; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; LATVIA; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84877059923     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283608695     Document Type: Article

References (18)

1. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet 2009; 126:499-510.
2. de Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 2005; 230:153-186.
3. McKenzie HA, Fung C, Becker TM, Irvine M, Mann GJ, Kefford RF, et al. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Hum Mutat 2010; 31:692-701.
4. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressorlocus. Mutat Res 2005; 576 (1-2):22-38.
5. Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, et al. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res 2007; 17:185-191.
6. Pjanova D, Molven A, Akslen LA, Engele L, Streinerte B, Azarjana K, et al. Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma Res 2009; 19:119-122.
7. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12:97-99.
8. Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 2013; 50:264-270.
9. Harland M, Taylor CF, Bass S, Churchman M, Randerson-Moor JA, Holland EA, et al. Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. Genes Chromosomes Cancer 2005; 43:128-136.
10. Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barrett JH, et al. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 2005; 44:292-300.
11. Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, et al. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 2008; 47:175-184.
12. Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 2000; 28:45-57.
13. Molven A, Grimstvedt MB, Steine SJ, Harland M, Avril MF, Hayward NK, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 2005; 44:10-18.
14. Pollock PM, Stark MS, Palmer JM,Walters MK, Aitken JF, Martin NG, et al. Mutation analysis of the CDKN2A promoter in Australian melanoma families. Genes Chromosomes Cancer 2001; 32:89-94.
15. Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosomes Cancer 2001; 31:398-401.
16. Loo JC, Liu L, Hao A, Gao L, Agatep R, Shennan M, et al. Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene 2003; 22:6387-6394.
17. Harland M, Mistry S, Bishop DT, Bishop JA. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Gen 2001; 10:2679-2686.
18. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-typep53. Mol Cell Biol 1998; 18:6457-6473.